Iovance Biotherapeutics (IOVA) – Research Analysts’ Recent Ratings Updates

Iovance Biotherapeutics (NASDAQ: IOVA) has recently received a number of price target changes and ratings updates:

• 9/18/2023 – Iovance Biotherapeutics had its price target lowered by analysts at Barclays PLC from $40.00 to $18.00. They now have an “overweight” rating on the stock.
• 9/15/2023 – Iovance Biotherapeutics had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $18.00 price target on the stock.
• 9/15/2023 – Iovance Biotherapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
• 9/15/2023 – Iovance Biotherapeutics had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $30.00 price target on the stock.
• 9/15/2023 – Iovance Biotherapeutics had its “buy” rating reaffirmed by analysts at Truist Financial Co.. They now have a $17.00 price target on the stock.
• 9/13/2023 – Iovance Biotherapeutics had its price target lowered by analysts at Stifel Nicolaus from $27.00 to $26.00. They now have a “buy” rating on the stock.
• 9/8/2023 – Iovance Biotherapeutics was upgraded by analysts at StockNews.com to a “sell” rating.
• 8/17/2023 – Iovance Biotherapeutics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/17/2023 – Iovance Biotherapeutics had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $18.00 price target on the stock.
• 8/16/2023 – Iovance Biotherapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $29.00 price target on the stock.
• 8/9/2023 – Iovance Biotherapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
• 8/9/2023 – Iovance Biotherapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $29.00 price target on the stock.
• 8/9/2023 – Iovance Biotherapeutics had its price target lowered by analysts at Robert W. Baird from $23.00 to $20.00.
• 7/26/2023 – Iovance Biotherapeutics was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.

Iovance Biotherapeutics Stock Performance

NASDAQ:IOVA opened at $5.93 on Tuesday. The company has a fifty day moving average of $6.74 and a two-hundred day moving average of $6.92. The stock has a market capitalization of $1.47 billion, a PE ratio of -2.65 and a beta of 0.10. Iovance Biotherapeutics, Inc. has a fifty-two week low of $4.41 and a fifty-two week high of $10.85.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.34. The company had revenue of $0.24 million for the quarter, compared to analyst estimates of $3.91 million. During the same quarter in the prior year, the company posted ($0.63) earnings per share. Research analysts forecast that Iovance Biotherapeutics, Inc. will post -1.87 earnings per share for the current year.

Insider Transactions at Iovance Biotherapeutics

In other Iovance Biotherapeutics news, Director Wayne P. Rothbaum bought 5,000,000 shares of the company’s stock in a transaction dated Friday, September 15th. The stock was acquired at an average price of $5.30 per share, with a total value of $26,500,000.00. Following the completion of the acquisition, the director now directly owns 23,067,333 shares of the company’s stock, valued at $122,256,864.90. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On Iovance Biotherapeutics

A number of large investors have recently modified their holdings of the business. California State Teachers Retirement System grew its holdings in shares of Iovance Biotherapeutics by 47.2% during the second quarter. California State Teachers Retirement System now owns 235,573 shares of the biotechnology company’s stock worth $1,658,000 after buying an additional 75,519 shares in the last quarter. Nuveen Asset Management LLC grew its holdings in shares of Iovance Biotherapeutics by 3.4% in the second quarter. Nuveen Asset Management LLC now owns 2,229,281 shares of the biotechnology company’s stock valued at $15,694,000 after purchasing an additional 73,739 shares during the period. GTS Securities LLC purchased a new stake in shares of Iovance Biotherapeutics in the second quarter valued at about $440,000. Wells Fargo & Company MN grew its holdings in shares of Iovance Biotherapeutics by 52.5% in the second quarter. Wells Fargo & Company MN now owns 377,970 shares of the biotechnology company’s stock valued at $2,661,000 after purchasing an additional 130,053 shares during the period. Finally, Polar Asset Management Partners Inc. purchased a new stake in shares of Iovance Biotherapeutics in the second quarter valued at about $2,793,000. Hedge funds and other institutional investors own 81.85% of the company’s stock.

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer.